Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc (AGEN) is a clinical-stage biotechnology company pioneering novel immunotherapies to combat cancer and infectious diseases. This page provides centralized access to official press releases, financial updates, and scientific developments from Agenus, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships, alongside analyses of AGEN’s proprietary platforms like Retrocyte Display™ antibody technology. The curated news collection enables efficient monitoring of the company’s immuno-oncology pipeline and manufacturing advancements through its integrated cGMP facilities.
Key categories include earnings reports, therapy development updates, licensing agreements, and peer-reviewed research highlights. Bookmark this page to stay informed about AGEN’s innovations in checkpoint modulators, cell therapies, and vaccine adjuvants without navigating multiple sources.
Agenus (NASDAQ: AGEN) has announced it will present new data from its Phase 1 trial of botensilimab and balstilimab (BOT/BAL) combination therapy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients at the ESMO Gastrointestinal Cancers Congress 2025. The expanded study now includes 123 patients, representing a 60% increase in patient enrollment, and will feature updated findings on clinical activity, durability of response, and both median and 2-year overall survival data.
The presentation, led by Dr. Benjamin Schlechter from Dana Farber Cancer Institute, will take place on July 4, 2025, at 3:30 PM CEST in Barcelona, Spain.
Agenus (Nasdaq: AGEN), a leading immunological cancer treatment developer, has scheduled its first quarter 2025 financial results announcement for Monday, May 12th, before market opening.
The company will host a conference call and webcast at 8:30 a.m. ET the same day, featuring company executives who will discuss quarterly results and provide a corporate update. Interested parties can access the event through:
- Conference call registration (Conference ID: 73242)
- Live webcast via the company's investor relations website
- Alternative webcast link through Q4's platform
A replay of the conference call will be made available through both the company website and Q4's platform for those unable to attend the live session.
Agenus presented promising results from their NEOASIS study at the AACR Annual Meeting, showcasing the effectiveness of their botensilimab and balstilimab (BOT/BAL) combination therapy in treating various solid tumors.
Key findings from the Phase 2 neoadjuvant study include:
- For dMMR/MSI-H tumors: 90% pathological response rate, 80% major pathological response, and 70% complete response
- For pMMR/MSS tumors: 80% pathological response rate, 70% major pathological response, and 20% complete response
- In triple-negative breast cancer patients, 63% achieved major pathological response
The study demonstrated that just two doses of BOT/BAL could induce significant responses across multiple cancer types, including triple-negative breast cancer. Importantly, no dose-limiting toxicities were observed, and all patients proceeded to surgery as scheduled. The treatment shows particular promise in early-stage cancers, including those typically resistant to immunotherapy.
Agenus (NASDAQ: AGEN) presented updated data from its Phase 1 study evaluating the combination of botensilimab (BOT) and balstilimab (BAL) in hepatocellular carcinoma (HCC) at the AACR Annual Meeting. The study focused on 19 heavily pretreated patients who had progressed after standard treatments, including immunotherapies.
Key results from the trial showed:
- Overall response rate: 17%
- Disease control rate: 72%
- Median progression-free survival: 4.4 months
- Median overall survival: 12.3 months
The BOT/BAL combination demonstrated durable responses in treatment-refractory HCC patients, including those who progressed on atezolizumab/bevacizumab. The safety profile remained consistent with previous cohorts and was manageable. The study results suggest potential clinical utility in treating advanced HCC patients who have options after progression on immune checkpoint inhibitors.